Should Nanobots Be Used to Treat Cancer? By: Student ID 0017404 - PowerPoint PPT Presentation

Dec 26, 2022 •207 likes •302 views

Should Nanobots Be Used to Treat Cancer? By: Student ID 0017404 Overview Three Reasons Why Nanobots Counterarguments Should Be Used to Treat Cancer Q&A Session Refutation FIRST ARGUMENT Nanobots can detect early stages of cancer cell

Should Nanobots Be Used to Treat Cancer? By: Student ID 0017404
Overview Three Reasons Why Nanobots Counterarguments Should Be Used to Treat Cancer Q&A Session Refutation
FIRST ARGUMENT Nanobots can detect early stages of cancer cell formation .
Second Argument Nanobots can diagnose and treat diabetes.
Third Argument Nanobots can perform CNS surgeries safer than traditional surgeries .
Counterargument Nanobots may have the potential to destroy other cells.
Refutation Nanobots are designed to operate on specific sites.
Nanobots can detect early stages of cancer cell formation. Nanobots can diagnose and treat SUMMARY diabetes. OF Nanobots can perform CNS surgeries TODAY’S safer than traditional surgeries. TALK Nanobots may have the potential to destroy cells. Nanobots are designed to operate on specific sites.
Questions?

Download Presentation

Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

Targeting Src to treat antiestrogen resistant breast cancer breast cancer Joyce Slingerland

Targeting Src to treat antiestrogen resistant breast cancer breast cancer Joyce Slingerland Braman Family Breast Cancer Institute Sylvester Comprehensive Cancer Center U of Miami Miller School of Medicine p27- key mediator of G1 arrest

699 views • 42 slides

End Cervical Cancer: Prevent, Treat, Care UN Joint Global Programme on Cervical Cancer

End Cervical Cancer: Prevent, Treat, Care UN Joint Global Programme on Cervical Cancer Prevention and Control #cxca JOINT PROGRAMME MEMBERS PRIORITIES COUNTRY LEVEL Support countries in the design and implementation of a comprehensive

390 views • 15 slides

How I Treat Metastatic Colorectal Cancer Making Sense of the Data Axel Grothey West Cancer

How I Treat Metastatic Colorectal Cancer Making Sense of the Data Axel Grothey West Cancer Center, U Tennessee The Luxury of So Many Options . . . How Do We Personalize? Patient X Patient Y Patient Z PD-1 mAb What influences treatment

284 views • 27 slides

How to treat men with pN1 Prostate Cancer? Alberto BOSSI Dept of Radiation Oncology Research

Node Positive Prostate Cancer: How to treat men with pN1 Prostate Cancer? Alberto BOSSI Dept of Radiation Oncology Research Support Ipsen, Janssen, Sanofi Employee Gustave Roussy, Villejuif, France Consultant Astellas, Bard, Elekta, Ipsen

820 views • 44 slides

A Cancer Immunotherapy Company Harnessing the Human Immune System To Diagnose and Treat Cancer

A Cancer Immunotherapy Company Harnessing the Human Immune System To Diagnose and Treat Cancer March 2015 1 Disclaimer Forward Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS AND PROJECTIONS. THE COMPANY MAKES NO

469 views • 26 slides

5/1/2009 Do we need biopsy to treat early inoperable lung cancer? Frank J. Lagerwaard MD PhD VU

5/1/2009 Do we need biopsy to treat early inoperable lung cancer? Frank J. Lagerwaard MD PhD VU University medical center Amsterdam, The Netherlands Perspectives in Lung Cancer, Bruxelles, 2009 VUmc Amsterdam Pathological verification of malignancy

444 views • 9 slides

Phase 2 Randomization: 1:1:1 Switch over to ARM A n=132 Treat to Niraparib Bevacizumab

ENGOT-OV24-NSGO/AVANOVA Phase 2 Randomization: 1:1:1 Switch over to ARM A n=132 Treat to Niraparib Bevacizumab PD/toxicity 300mg OD d1-21 15mg/kg q3w Platinum- sensitive Ovarian Cancer ARM B Treat to Randomize Niraparib

319 views • 7 slides

Asymptomatic Metastatic Castrate Resistant Prostate Cancer Miki Haifler, MD, M.Sc Urologic

Asymptomatic Metastatic Castrate Resistant Prostate Cancer Miki Haifler, MD, M.Sc Urologic Oncology Department of Urology Shamir (Assaf Haroffeh) Medical Center Sackler Faculty of Medicine Tel-Aviv University To Treat or Not to Treat? And

649 views • 19 slides

How to best treat cN1 prostate cancer? Karim Fizazi Institut Gustave Roussy France Disclosure

How to best treat cN1 prostate cancer? Karim Fizazi Institut Gustave Roussy France Disclosure Participation to advisory boards/honorarium for: Astellas, AAA, Bayer, Curevac, Janssen, MSD, Orion, Sanofi Randomized controlled trials in

208 views • 18 slides

How I (We) Treat CTCL Youn H Kim, MD Multidisciplinary Cutaneous Lymphoma Group Stanford Cancer

How I (We) Treat CTCL Youn H Kim, MD Multidisciplinary Cutaneous Lymphoma Group Stanford Cancer institute School University School of Medicine NCCN NHL Disclosures of Youn Kim TCL member Company Research Speakers Advisory Employee

1.99k views • 52 slides

A Cancer Immunotherapy Company Harnessing the Human Immune System To Diagnose and Treat Cancer

A Cancer Immunotherapy Company Harnessing the Human Immune System To Diagnose and Treat Cancer January 2015 January 2015 1 Disclaimer Disclaimer Forward Looking Statements THIS PRESENTATION CONTAINS FORWARD LOOKING STATEMENTS AND

329 views • 28 slides

A Cancer Immunotherapy Company Focused On The Development of

A Cancer Immunotherapy Company Focused On The Development of Vaccines And An<bodies to Diagnose and Treat Cancer Rodman & Renshaw 16 th Annual

689 views • 19 slides

How I treat high-risk MDS Matteo G Della Porta Cancer Center IRCCS Humanitas Research Hospital

How I treat high-risk MDS Matteo G Della Porta Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Milano, Italy matteo.della_porta@hunimed.eu Clinical decision making in MDS - Critical issues How we can define

540 views • 22 slides

Finite Element Modeling of the TREAT (as Built) Reactor and a Possible 20% Enriched Fuel TREAT

Finite Element Modeling of the TREAT (as Built) Reactor and a Possible 20% Enriched Fuel TREAT PATRICK MCDANIEL NIMA FATHI CASSIANO DE OLIVEIRA TREAT Modeling The Treat reactor was built in 1959 to test fuel for fast reactors It operated

657 views • 17 slides

2/13/14 How I Treat Oral Chronic Graft-vs-Host Disease Nathaniel S. Treister, DMD, DMSc

2/13/14 How I Treat Oral Chronic Graft-vs-Host Disease Nathaniel S. Treister, DMD, DMSc Associate Surgeon, Dana-Farber-Brigham & Womens Cancer Center Assistant Professor, Harvard School of Dental Medicine Boston, MA o No

492 views • 10 slides

1 | TREAT-NMD 17 th September 2020 AGENDA 1. Welcome and introduction from participants 2.

LGMD CORE DATASET PROJECT 1 ST MEETING 1 | TREAT-NMD 17 th September 2020 AGENDA 1. Welcome and introduction from participants 2. Housekeeping and ground-rules 3. TREAT-NMD and TGDOC overview 4. Introduction to TREAT-NMD LGMD Global

1.28k views • 48 slides

Lower bounds for width-restricted with Lemmas The Pigeonhole clause learning Principle The

Width-restricted clause learning Jan Johannsen Resolution Trees Lower bounds for width-restricted with Lemmas The Pigeonhole clause learning Principle The Ordering Principle Small Width Jan Johannsen Formulas Institut f ur

272 views • 25 slides

They Say, I Say: TEMPLATES FOR WRITING ABOUT RESEARCH They Say, I Say (Graff, Birkenstein, and

They Say, I Say: TEMPLATES FOR WRITING ABOUT RESEARCH They Say, I Say (Graff, Birkenstein, and Durst, 2012) shows students that writing well means entering a conversation, summarizing others (they say) to set up ones own argument (I say)

108 views • 8 slides

FY2012 Results Presentation By Chris Sutherland, Managing Director 30 May 2012 Important notice

FY2012 Results Presentation By Chris Sutherland, Managing Director 30 May 2012 Important notice and disclaimer The information contained in this presentation is for information purposes only and does not constitute an offer to issue, or arrange

507 views • 24 slides

PORT VALDEZ WEATHER BUOY DEPLOYMENT UPDATE VMT WEATHER BUOY BACKGROUND INFORMATION

9/19/19 PORT VALDEZ WEATHER BUOY DEPLOYMENT UPDATE VMT WEATHER BUOY BACKGROUND INFORMATION Location: VMT off of Jackson Point between Berths 1 and 3 Date Deployed: May 16, 2019 Information provided: Current speed and

242 views • 7 slides

NI LE RI VER BASI N 1. Water Event Intensity Scale 2. Power relations: Hegemony and Counter-

NI LE RI VER BASI N 1. Water Event Intensity Scale 2. Power relations: Hegemony and Counter- Hegemony WATER EVENT INTENSITY SCALE BAR EVENT DESCRIPTION SCALE 7 Voluntary unification into one nation International Freshwater Treaty or

472 views • 13 slides

r tPr q tts s

trt t tPr trt t q t rr qtrs s

430 views • 16 slides

From Text Message to Research Paper: Teaching the Text Message Generation Heidi Wright Ohio

From Text Message to Research Paper: Teaching the Text Message Generation Heidi Wright Ohio State University Introduction and Organization Origins- SIUC 2006 Increased number of tasks and shorter time frame Insufficient background

241 views • 22 slides

Presented by Abu Zakariya Agenda 1. Some Important Definitions 2. Dawah Strategy - Why Jesus is

Presented by Abu Zakariya Agenda 1. Some Important Definitions 2. Dawah Strategy - Why Jesus is Not God - Why Jesus is Not the Son of God - Why Jesus is a Servant of God What is Christianity? Lets start with a definition as its

1.23k views • 110 slides